Marked Chart Marked Chart Closed

The Marked Chart Wire · Health

Zai Lab

Zai Lab secures coverage for five drugs in China

Zai Lab Limited confirmed that five of its commercial treatments, including KarXT and VYVGART Hytrulo, are now part of the national reimbursement program for 2026.

ZLAB-0.9%

Illustration for the Health desk

The stocks in this story

  1. ZLAB-0.9%Zai Lab$21.92

Prices from Based on Thu, Nov 19 close · Opens Fri 9:30 AM ET. Each tile opens the stock's chart and news.

New to this? Read: Reading a stock chart

More Health news

Illustration for the Health desk

Biohaven

Biohaven shares phase 1 results for BHV-1530

Biohaven disclosed early trial data for its antibody-drug conjugate BHV-1530. The findings showed that patients with FGFR3-altered cancers experienced shrinkage of tumors and other clinical benefits.

Fast headlines, summarized. Not verified and not advice. Check the full story before you act.